Hidradenitis Suppurativa

This interview with Steven Daveluy, MD, features a discussion of hidradenitis suppurativa, cutaneous lymphoma, and addressing racial disparities.

This prospective observational study suggests that there are differences between the gut microbiome compositions of pediatric patients and others with HS.

In this cross-sectional study, investigators looked at the relationship between neighborhood-level socioeconomic status and hidradenitis suppurativa.

This episode of the SOCS podcast features an in-depth discussion between Tiffany Mayo, MD, Steven Daveluy, MD, and patient advocate Jasmine Ivanna Espy.

These data highlight the susceptibility loci shared between HS and other inflammatory diseases among those with this condition.

This interview with Christopher Sayed, MD, features a discussion about his team’s recent findings on bimekizumab for hidradenitis suppurativa.

These pivotal phase 3 data on povorcitinib were the results of the STOP-HS clinical trial, with results suggesting both efficacy and safety for hidradenitis suppurativa.

These data presented at AAD 2025 indicate sustained 2-year disease control in key hidradenitis suppurativa (HS) symptoms with bimekizumab-bkzx treatment.

This interview with Chovatiya highlights his portion of the ‘Skin of Color’ talk at the American Academy of Dermatology conference.

Data from AAD 2025 examine the effect of GLP-1 RAs on HS among patients with overweight or obesity.

These data point to the necessity of quality and usability when using smartphone photographs of skin conditions in emergency departments.

These data provide a potential option for those suffering from hidradenitis suppurativa, as off-label treatment with botulinum toxin type X led to positive findings in patients.

This analysis highlights the major risk factors resulting in limited use of oral JAKi for patients with hidradenitis suppurativa, including smoking, obesity, hypertension, and age.

These data expand upon existing literature on pediatric HS and racial differences among patients based on management, presentation, and severity.

These data highlight a variety of comorbidities linked to dermatologic diseases in children with obesity, including common comorbidities such as asthma.

New 2-year data from the BE HEARD program shed further light on the role bimekizumab in treatment algorithms for HS.

In this study, investigators highlighted factors associated with active hidradenitis suppurativa over the age of 50 such as smoking, male gender, and later onset of disease.

In this analysis, investigators conclude that health-related quality of life and clinical burdens are greater among patients with hidradenitis suppurativa and draining tunnels.

This literature review explored the topic of hidradenitis suppurativa management during pregnancy and lactation, highlighting data available on this topic.

UCB announced that a new dosing option for bimekizumab-bkzx is now available through prescription for conditions such as psoriasis, hidradenitis suppurativa, and psoriatic arthritis.

These findings highlight the value in understanding and recognizing gender differences in patient experiences with hidradenitis suppurativa and their impact on life quality.

Patients in this post-hoc analysis with elevated CRP were found to have a higher BMI and more severe hidradenitis suppurativa.

In this analysis, a retrospective and multi-center study was conducted to determine any predictors of biological therapy intensification in individuals with HS.

In this analysis, investigators conducted a systematic review of studies evaluating the effects of smoking tobacco on surgical outcomes for those with hidradenitis suppurativa.

Study findings suggest an interplay between social determinants of health and HS, especially among underrepresented patient populations.